Senseonics Holdings Inc (SENS) Kazanmak

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. The company is headquartered in Germantown, Maryland and currently employs 130 full-time employees. The company went IPO on 2015-03-04. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.